Statistics for Revance Therapeutics (id:6423 RVNC)

Valuation metrics

Market cap

402.82M

Enterprise value

698.00M

Trailing P/E (ttm)

-0.97

Forward P/E

-4.04

PEG ratio

-4.04

Price/Sales (ttm)

1.57

Price/Book (mrq)

-2.38

Enterprise Value/Revenue

2.72

Enterprise Value/EBITDA

-3.72

Overview

Shares outstanding

104.90M

Float

91.29M

Shares short

10.00M

% Held by insiders

0.09%

% Held by institutions

0.82%

Average volume (10 days)

3.60M

Average volume (90 days)

Price summary

52-Week low

2.30

52-Week high

9.74

52-Week change

-93.03%

Beta

0.95

50-Day moving average

5.24

200-Day moving average

4.61

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-71.78%

Operating margin

-53.87%

Operational effectiveness

Return on assets

-24.36%

Return on equity

213.71%

Income statement

Revenue (ttm)

2.66

Revenue per share (ttm)

2.66

Quarterly revenue growth (yoy)

Gross profit (ttm)

159.68M

EBITDA

-187,624,000.00

Net income to common (ttm)

-303,012,992.00

Diluted EPS (ttm)

-3.34

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

184.08M

Total cash per share (mrq)

1.76

Total debt (mrq)

483.45M

Total Debt/Equity (mrq)

-2.97

Current ratio (mrq)

411.90%

Book value per share (mrq)

-1.55

Cash flow

Cash flow statement

-190,888,000.00

Levered free cash flow (LFCF)

-167,852,256.00